

I. AMENDMENTS

In the Claims:

Please amend claims 1, 2, 8, 11 and 15-17, as shown below by deleting the stricken-through material and inserting the underlined material as follows:

1. (Currently Amended) A method for prophylaxis or treating Sinusoidal Obstruction Syndrome in a human patient in need thereof, comprising administering an effective amount of a matrix metalloproteinase inhibitor.

2. (Currently Amended) A method for prophylaxis or treating chemotherapy- or radiation-induced liver disease in a human patient in need thereof, comprising administering an effective amount of a matrix metalloproteinase inhibitor.

3. (Previously Amended) The method of claim 2, wherein said chemotherapy-induced liver disease includes Sinusoidal Obstruction Syndrome, nodular regenerative hyperplasia peliosis hepatic, immunosuppression-induced hepatic venoocclusive disease, and sinusoidal dilatation.

4. (Previously Amended) The method of claims 1 or 2, wherein said matrix metalloproteinase inhibitor is doxycycline or 2-[1(4-bisphenylsulfonyl)amino]-3-phenyl-propionic acid.

5. (Previously Amended) The method of claim 4, wherein said matrix metalloproteinase inhibitor is doxycycline.

6. (Previously Amended) The method of claim 5 wherein 15 mg/kg of said doxycycline is administered twice daily.

7. (Previously Amended) The method of claim 4, wherein said matrix metalloproteinase inhibitor is 2-[1(4-bisphenylsulfonyl)amino]-3-phenyl-propionic acid.

8. (Currently Amended) The method of claim 7 wherein 100-200 μg ~~mg~~/hour of said 2-[1(4-bisphenylsulfonyl)amino]-3-phenyl-propionic acid is administered.

9. (Previously Amended) The method of claims 1 or 2 wherein said matrix metalloproteinase inhibitor is administered for up to 4 weeks.

10. (Previously Amended) The method of claims 1 or 2, wherein said matrix metalloproteinase inhibitor is Marimastat, Prinomastat, RS-130,830, (N-hydroxy-2(R)-[[4-methoxysulfonyl](3-picolyl) amino]-3-methylbutamide hydrochloride) monohydrate, Solimastat, BAY 12-9566, (3(R)(cyclopentylmethyl)-2(R)-[(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)methyl]-4-oxo-4-piperidinobutyrohydroxamic acid), BMS-272591, Ilomastat, D2163, Metastat, Neovastat, or Periostat.

11. (Currently Amended) A method for prophylaxis or treating chemotherapy or radiation induced liver disease in a patient in need thereof comprising administering an effective dose of a matrix metalloproteinase inhibitor selected from doxycycline or 2-[(4-bipheylsulfonyl)amino]-3-phenyl-propionic acid.

12. (Previously Amended) The method of claim 11, wherein said matrix metalloproteinase inhibitor is doxycycline.

13. (Previously Amended) The method of claim 12, wherein 15 mg/kg of said doxycycline is administered twice daily.

14. (Previously Amended) The method of claim 11, wherein said matrix metalloproteinase inhibitor is 2-[1(4-bisphenylsulfonyl)amino]-3-phenyl-propionic acid.

15. (Currently Amended) The method of claim 14, wherein 100-200 μg ~~mg~~/hour of said 2-[1(4-bisphenylsulfonyl)amino]-3-phenyl-propionic acid is administered.

16. (Currently Amended) A method for prophylaxis or treating chemotherapy or radiation induced liver disease in a patient in need thereof comprising administering 15 mg/kg of doxycycline twice daily.

17. (Currently Amended) A method for prophylaxis or treating chemotherapy or radiation induced liver disease in a patient in need thereof, comprising administering 100-200 μg ~~mg~~/hour of 2-[1(4-bisphenylsulfonyl)amino]-3-phenyl-propionic acid.

Please add new claims 18 and 19, as follows:

18. (New) The method of claim 1, wherein the patient suffers from or is susceptible to Sinusoidal Obstruction Syndrome.

19. (New) The method of any one of claims 2, 11 or 16, wherein the patient suffers from or is susceptible to chemotherapy- or radiation-induced liver disease.